By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Enanta Pharmaceuticals, Inc. 

500 Arsenal Street

Watertown  Massachusetts  02472  U.S.A.
Phone: 617-607-0800 Fax: 617-607-0530


SEARCH JOBS


Industry
Pharmaceutical






Company News
Enanta Pharmaceuticals, Inc. To Present At Barclays Global Healthcare Conference 3/4/2015 11:11:03 AM
Enanta Pharmaceuticals, Inc. Announces JAMA Publication Of Results From AbbVie (ABBV)’s Study Of VIEKIRA PAK™ (Ombitasvir, Paritaprevir, Ritonavir Tablets; Dasabuvir Tablets) In Chronic Hepatitis C Patients With HIV-1 Co-Infection (TURQUOISE-I) 2/23/2015 11:21:14 AM
Enanta Pharmaceuticals, Inc. Announces AbbVie (ABBV) Submits New Drug Application To The Japanese Ministry Of Health, Labour And Welfare For Its Investigational, All-Oral, Treatment For Chronic Hepatitis C 2/12/2015 11:42:00 AM
Enanta Pharmaceuticals, Inc. To Present At 2015 Leerink Global Healthcare Conference 2/5/2015 11:48:12 AM
Enanta Pharmaceuticals, Inc. Reports Financial Results For Its Fiscal First Quarter Ended December 31, 2014 2/5/2015 11:44:11 AM
Enanta Pharmaceuticals, Inc. Announces 95 Percent SVR12 Rate In Abbvie’s Phase 3 Study Of All-Oral Treatment For Hepatitis C Virus In Japanese Patients 2/2/2015 10:58:20 AM
Enanta Pharmaceuticals, Inc. Announces European Commission (EC) Grants Marketing Authorizations For AbbVie (ABBV)’s VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets)... 1/16/2015 9:50:01 AM
Enanta Pharmaceuticals, Inc. To Present At The 33rd Annual J.P. Morgan Healthcare Conference 1/7/2015 9:53:46 AM
Enanta Pharmaceuticals, Inc. Announces FDA Approves AbbVie (ABBV)’s VIEKIRA PAK™ (Ombitasvir/Paritaprevir/Ritonavir Tablets; Dasabuvir Tablets) For The Treatment Of Chronic Genotype 1 Hepatitis C Virus 12/22/2014 12:13:55 PM
Enanta Pharmaceuticals, Inc. Added To The NASDAQ Biotechnology Index 12/15/2014 11:36:51 AM
123456789
//-->